Drugs Targeted Protein Degradation Treatment 
Covalent Modifiers
FEBRUARY 1, 2024
Covalent and noncovalent inhibitors of BTK have revolutionized the treatment of these cancers. Therefore, understanding mechanisms by which acquired mutations in BTK confer drug resistance and developing new therapies to overcome resistance are critically important.
SugarCone Biotech
OCTOBER 6, 2024
Cancer cell viability was reduced by 50% - 80% after 7 days treatment in vitro, however only limited in vivo data was shown in this paper. Because Trf1 is degraded as part of the degradation of the internalized protein complex, these EGFR-bright cells become iron-starved and die as a consequence.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BMG Labtech
MAY 22, 2024
Options for cell-based protein degrader assays Interest is growing in the use of targeted-protein degradation to induce the breakdown of disease-causing proteins after treatment with small molecule drugs.
Drug Target Review
OCTOBER 4, 2023
Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 1 However, efforts proved less effective than the original drugs, owing mostly to insufficient toxicity against cancer cells.
Sygnature Discovery
SEPTEMBER 25, 2023
Sygnature Discovery identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation.
Drug Target Review
JULY 23, 2024
This laid the groundwork for my career in drug discovery using novel modalities like small molecule inhibitors, antibodies, RNA interference (RNAi) and, currently, small molecule protein degraders – which are opportunities to change how we think about medicines. I’ve already had a number of ‘rocking chair’ moments in my career.
The Pharma Data
DECEMBER 21, 2020
. Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe. Captor’s Optigradeä platform is focused on improving the selectivity and performance of first-generation degrader drugs. TOKYO and CAMBRIDGE, England , Dec.
Expert insights. Personalized for you.
173 
Let's personalize your content